R317573

R317573 is an investigational small molecule antagonist of the corticotropin-releasing factor receptor type 1 (CRF1), developed by Janssen-Cilag (a subsidiary of Johnson & Johnson). It was primarily researched for the treatment of anxiety disorders and other stress-related mood disorders. The compound works by blocking the CRF1 receptor, a key component of the hypothalamic-pituitary-adrenal (HPA) axis that mediates the physiological and behavioral response to stress. R317573 reached Phase 2 clinical development, where it was evaluated in models such as 7.5% CO2-induced anxiety in healthy volunteers and studied for its effects on regional cerebral glucose metabolism in brain regions associated with emotional processing. Despite its clinical evaluation, there is no evidence of recent development, suggesting the program may have been discontinued.